Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
NCT ID: NCT04838678
Last Updated: 2025-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
100 participants
INTERVENTIONAL
2021-07-18
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation
NCT05153395
Acupuncture Treatment on Cerebral Blood Flow
NCT04346511
Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
NCT00930072
Assessment of Autonomic Neuronal Changes During Moderate Rise of Intracranial Pressure in Human
NCT01776801
Vascular Function and Uterine Fibroids
NCT02123069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Control
Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
Neuropeptide Y
intra-arterial infusion of neuropeptide Y
Hypertensive
Hypertensive adults who are not obese
Neuropeptide Y
intra-arterial infusion of neuropeptide Y
Obese
Obese adults who are not hypertensive
Neuropeptide Y
intra-arterial infusion of neuropeptide Y
Obese-hypertensive
Obese adults who are being treated for hypertension
Neuropeptide Y
intra-arterial infusion of neuropeptide Y
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuropeptide Y
intra-arterial infusion of neuropeptide Y
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypertensive - BMI\<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI\>30, age 18-55 Obese-hypertensive- BMI\>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring
Exclusion Criteria
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas Southwestern Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher Hearon
Assistant Instructor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU2020-0749
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.